Shire

AnHeart Therapeutics Expands U.S. Leadership With Development and Commercial Leads

Retrieved on: 
星期四, 十一月 9, 2023
Biotechnology, Health, Pharmaceutical, Clinical Trials, Oncology, FDA, Forest Laboratories, Seres, U.S. Commercial Service in Taiwan, Merck, Doctor of Philosophy, Development, Senior, Relay, Shire, Marketing, Lung cancer, Cancer, Therapy, ARIAD Pharmaceuticals, David Berry (inventor), Regulatory affairs, Pharmaceutical industry, Takeda

AnHeart Therapeutics (“AnHeart”), a global clinical-stage biopharmaceutical company developing novel precision therapies for people with cancer, today announced the appointments of Guilin Huang as Senior Vice President, Development and Amy Muse as Vice President, U.S. Commercial.

Key Points: 
  • AnHeart Therapeutics (“AnHeart”), a global clinical-stage biopharmaceutical company developing novel precision therapies for people with cancer, today announced the appointments of Guilin Huang as Senior Vice President, Development and Amy Muse as Vice President, U.S. Commercial.
  • Amy joins AnHeart with more than 20 years of commercial experience in the pharmaceutical and biotech industry.
  • Amy will lead commercial strategy for AnHeart’s investigational precision therapies in the United States, focusing initially on preparing AnHeart for the commercial launch of taletrectinib.
  • Prior to Takeda, Amy held several commercial roles, including marketing and sales positions, at Shire, Forest Laboratories, and Merck and Co.

TearSolutions, Inc. Appoints Robert Dempsey to its Board of Directors

Retrieved on: 
星期三, 十一月 1, 2023
FDA, Therapy, Takeda, Telecanthus, Drug development, DED, Safety, Patient, Shire, Pharmaceutical industry, Ophthalmology, Novartis

CHARLOTTESVILLE, Va., Nov. 01, 2023 (GLOBE NEWSWIRE) -- TearSolutions, Inc. , a privately held biotech company developing potentially disruptive therapies for the treatment of Dry Eye Disease (DED) and other ocular surface related diseases, today announced that Robert Dempsey has been appointed to the Company’s Board of Directors.

Key Points: 
  • CHARLOTTESVILLE, Va., Nov. 01, 2023 (GLOBE NEWSWIRE) -- TearSolutions, Inc. , a privately held biotech company developing potentially disruptive therapies for the treatment of Dry Eye Disease (DED) and other ocular surface related diseases, today announced that Robert Dempsey has been appointed to the Company’s Board of Directors.
  • “Robert is a proven industry leader with extensive and highly relevant experience in Ophthalmology and DED,” said Anil Asrani, President and CEO of TearSolutions.
  • His widespread experience in Ophthalmology stems from diverse leadership roles across commercial, business development, medical affairs, and venture-backed startups.
  • Currently, Robert serves as the Chief Executive Officer at AsclepiX Therapeutics focused on advancing an integrin regulating peptide for posterior segment diseases.

Anokion Strengthens its Senior Leadership with Promotions and New Appointment

Retrieved on: 
星期四, 九月 7, 2023
Biotechnology, Pharmaceutical, Health, Clinical Trials, Laboratory, Drug development, University, University of Hartford, Doctor of Philosophy, Abbott Laboratories, CMC, University of Florida, Immune tolerance, Pharmacokinetics, MBA, Research, Boston University, Chemistry, Shire, Acquisition, Novartis, Rensselaer Polytechnic Institute, AbbVie, Patient, Chemical engineering, Autoimmune disease, DMPK, Alexion, Growth, Merck Serono, Cadent, Therapy, Merrimack Pharmaceuticals, Microbiology, Management

Anokion SA , a clinical-stage biotechnology company focused on treating autoimmune disease by restoring normal immune tolerance, today announced a series of senior leadership promotions and a new senior appointment, effective immediately.

Key Points: 
  • Anokion SA , a clinical-stage biotechnology company focused on treating autoimmune disease by restoring normal immune tolerance, today announced a series of senior leadership promotions and a new senior appointment, effective immediately.
  • Kristie Grebe, Ph.D., has been promoted to chief scientific officer, Michael DiLeo has been promoted to senior vice president, corporate development and business operations and Nicole Luosey joins Anokion as senior vice president, product and development operations.
  • “We are pleased to announce these strategic leadership promotions and the expansion of our senior leadership team, all of which are a testament to the progress we have made advancing innovative solutions for autoimmune diseases,” said Deborah Geraghty, Ph.D., chief executive officer of Anokion.
  • Mike’s successful journey within Anokion, and deep contributions in corporate and business development, will continue to drive our growth and partnerships.

Azitra Adds Biotech Leaders Barbara Ryan and John Schroer to Its Board of Directors

Retrieved on: 
星期三, 七月 19, 2023
Bear Stearns, Partnership, University, Senior advisor, Medication, Ernst & Young, Wall Street, Allianz Global Investors, MBA, History, Deutsche Bank, University of Wisconsin–Madison School of Education, Editorial, Cardinal Health, Bayer, Shire, Patient, Sanofi–Translate Bio COVID-19 vaccine, Ernst, Mink, Knowledge, PIPES, Indivior, LP, Therapy, NYSE, Skin, Pharmaceutical industry, Esperies

BRANFORD, Conn., July 19, 2023 /PRNewswire/ -- Azitra, Inc. (NYSE American: AZTR), a clinical-stage biopharmaceutical company focused on developing innovative therapies for precision dermatology, today announced the addition of two members to its board of directors, Barbara Ryan and John Schroer.

Key Points: 
  • BRANFORD, Conn., July 19, 2023 /PRNewswire/ -- Azitra, Inc. (NYSE American: AZTR), a clinical-stage biopharmaceutical company focused on developing innovative therapies for precision dermatology, today announced the addition of two members to its board of directors, Barbara Ryan and John Schroer.
  • "We are thrilled to further strengthen the Azitra team by welcoming Barbara and John to our board and by leveraging their wealth of knowledge in biotech, corporate strategy, and capital markets," said Francisco Salva, President and CEO of Azitra.
  • "Both Barbara and John are widely recognized leaders in biotech, and their additions to Azitra's board will be invaluable as we grow the company to support clinical trials and our partnership with Bayer."
  • Barbara Ryan is a Board Member of Indivior PLC and MiNK Therapeutics, the CEO of Barbara Ryan Advisors, and a Senior Advisor at Ernst & Young.

Why is there so much confusion and fearmongering over WA's new Aboriginal Cultural Heritage Act?

Retrieved on: 
星期三, 七月 5, 2023
Exercise, Mineral, Native title in Australia, Native Title Act 1993, Disclosure, Aboriginal Heritage Act 1972, Fear, Public, Rio Tinto, Government, Shire, Climate change, Iron, Common heritage of humanity, Time, Mining, First Nations, Confusion, Copper, Commonwealth, National Heritage List (Australia), Ownership, Water resources, Lithium, Farmer, Tourism, Whaling, Uranium mining, Aborigine

There has been a flurry of scaremongering recently about Western Australia’s new Aboriginal Cultural Heritage Act, which came into effect on July 1.

Key Points: 
  • There has been a flurry of scaremongering recently about Western Australia’s new Aboriginal Cultural Heritage Act, which came into effect on July 1.
  • The act aims to better reflect the aspirations of Aboriginal people in government and business decisions that impact their cultural heritage.

Why was this new law instituted?

    • Those reforms narrowed the definition of Aboriginal heritage, weakening the protection of sacred sites to enable mining projects and other developments.
    • The law was developed over a period of five years and involved extensive consultation with many groups from all over WA.

What does the new act try to do?

    • Once tangible pieces of cultural heritage are destroyed, they are gone forever.
    • This is why the act aims to strike a better balance between the interests of different land users and stakeholder groups.
    • The new law includes stronger protections for significant sites and broader definitions of Aboriginal cultural heritage.

Is all of the concern justified? Why is there so much confusion?

    • Despite the aim of striking a better balance between different stakeholder interests, many groups remain concerned about the act.
    • Farmers say the changes may delay their normal operations and impede their ability to work the land.
    • What will be required is adequate resourcing for the new local Aboriginal cultural heritage services and the new Aboriginal Cultural Heritage Council.
    • Public workshops and education sessions will be offered for anyone who is uncertain about the new requirements, as well.

Is the new law strong enough?

    • In the past, the minister has routinely prioritised mining and other developments over Aboriginal heritage protection.
    • The First Nations Heritage Protection Alliance has called for overarching federal legislation to ensure Indigenous self-determination and consent rights on cultural heritage are codified into Commonwealth law.
    • The vision sees Aboriginal people as the custodians of their own heritage, supported by strong and consistent heritage management policies across all states.
    • Despite some improvement to the cultural heritage law in WA, more needs to be done.

uniQure Announces Leadership Addition to Support Advancement of Clinical Programs

Retrieved on: 
星期一, 六月 26, 2023
Employment, American University, Abbott Laboratories, American University of Beirut, Research, Rheumatoid arthritis, Ulcerative colitis, Yale School of Medicine, Shire, SOD1, Novartis, Patient, Haemophilia, Psychiatry, Biology, ALS, RSU, Medical device, Pharmaceutical industry, EU, Galápagos Islands, Pfizer

He will report to Matt Kapusta, Chief Executive Officer of uniQure, and will be based in the Company’s Basel, Switzerland office.

Key Points: 
  • He will report to Matt Kapusta, Chief Executive Officer of uniQure, and will be based in the Company’s Basel, Switzerland office.
  • Dr. Abi-Saab will be responsible for leading all clinical research and development, regulatory affairs, medical affairs, and program management at uniQure.
  • Under his leadership, more than 30 molecules have advanced through clinical development leading to several approvals in the US, EU and Canada.
  • I am happy to welcome Walid to the uniQure leadership team at this exciting time for the Company as we advance our clinical programs for Huntington’s disease and other serious diseases.”
    “I am very excited to join uniQure at this very promising moment for the Company,” stated Dr. Abi-Saab.

NetEase announces "Lord of the Rings" Game Fanfiction Contest

Retrieved on: 
星期三, 三月 29, 2023
Warner, Elf, Lord, Hobbiton Movie Set, SLG, Shire, NetEase, Dwarf, Google Play, Imagination, Hobbit, Film industry, Mordor

GUANGZHOU, China, March 29, 2023 /PRNewswire/ -- The SLG game released by NetEase is organizing a fanfiction contest for its character Mathom Peddler, where winners will receive round-trip tickets to visit the Hobbiton movie set in New Zealand.

Key Points: 
  • GUANGZHOU, China, March 29, 2023 /PRNewswire/ -- The SLG game released by NetEase is organizing a fanfiction contest for its character Mathom Peddler, where winners will receive round-trip tickets to visit the Hobbiton movie set in New Zealand.
  • The Lord of the Rings: Rise to War is a Warner Bros.-licensed real-time strategy game set in Middle-earth.
  • Moreover, as a season-based game, players can choose the season they want to experience, and play the game under various rules and settings.
  • The fanfiction contest is centered around Mathom House, a setting in the original fiction.

NetEase announces "Lord of the Rings" Game Fanfiction Contest

Retrieved on: 
星期三, 三月 29, 2023
Warner, Elf, Lord, Hobbiton Movie Set, SLG, Shire, NetEase, Dwarf, Google Play, Imagination, Hobbit, Film industry, Mordor

GUANGZHOU, China, March 29, 2023 /PRNewswire/ -- The SLG game released by NetEase is organizing a fanfiction contest for its character Mathom Peddler, where winners will receive round-trip tickets to visit the Hobbiton movie set in New Zealand.

Key Points: 
  • GUANGZHOU, China, March 29, 2023 /PRNewswire/ -- The SLG game released by NetEase is organizing a fanfiction contest for its character Mathom Peddler, where winners will receive round-trip tickets to visit the Hobbiton movie set in New Zealand.
  • The Lord of the Rings: Rise to War is a Warner Bros.-licensed real-time strategy game set in Middle-earth.
  • Moreover, as a season-based game, players can choose the season they want to experience, and play the game under various rules and settings.
  • The fanfiction contest is centered around Mathom House, a setting in the original fiction.

Inozyme Pharma Reports Full Year 2022 Financial Results and Provides Business Highlights

Retrieved on: 
星期三, 三月 22, 2023
PD, Marketing, Biogen, Head, G&A, MBA, Science, Patient, Investment, Microsoft Access, Shire (pharmaceutical company), Infant, R, Research and development, EAP, Therapy, Research, Kidney disease, Consultant, UCB, Shire, TKT, FDA, IND, Safety, Myasthenia gravis, Multiple sclerosis, Administration, PXE, Master of Science, Calciphylaxis, Market Access Program, PK, CRISPR, Clinical trial, Channel, ESKD, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Food, Pharmaceutical industry, Dietary supplement, Management, Nursing, Cryptocurrency

BOSTON, March 22, 2023 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (Nasdaq: INZY), a clinical- stage rare disease biopharmaceutical company developing novel therapeutics for the treatment of pathologic mineralization and intimal proliferation, today reported financial results for the full year ended December 31, 2022, and provided recent business highlights. The Company also today announced that founding chief executive officer (CEO), Axel Bolte, MSc, MBA, will retire from his current role and that Douglas A. Treco, Ph.D., chairman of the Company’s board of directors (Board), will succeed Mr. Bolte as the CEO of the Company, effective April 1, 2023.

Key Points: 
  • BOSTON, March 22, 2023 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (Nasdaq: INZY), a clinical- stage rare disease biopharmaceutical company developing novel therapeutics for the treatment of pathologic mineralization and intimal proliferation, today reported financial results for the full year ended December 31, 2022, and provided recent business highlights.
  • I look forward to continuing to benefit from his experience as a senior advisor and Board member,” said Dr. Treco.
  • Axel Bolte, MSc, MBA, the Company’s founding CEO will retire and continue to work with Inozyme as a senior advisor and serve on the Board.
  • Dr. Winton most recently served as senior vice president and head of the Multiple Sclerosis franchise for Biogen’s US organization.

Jasper Therapeutics Appoints Industry Veteran Vishal Kapoor to its Board of Directors

Retrieved on: 
星期五, 二月 17, 2023
MBA, Ophthalmology, NPS, Partner, Genentech, Pfizer, Graduate School of Economics, Finance, and Management, Corporation, Acquisition, Columbia University, Shire, Therapy, Risk, MDS, Conditional sentence, Columbia Business School, CD117, Shire (pharmaceutical company), Syndrome, Pharmaceutical industry, Ranibizumab, Iver C. Weilbach & Co., Biology, Jasper

Mr. Kapoor has been a Partner of Avego Management, LLC, an affiliate of Velan Capital, since January 2021, leading their life sciences venture investing strategy.

Key Points: 
  • Mr. Kapoor has been a Partner of Avego Management, LLC, an affiliate of Velan Capital, since January 2021, leading their life sciences venture investing strategy.
  • He was also President of Amplitude Healthcare Acquisition Corporation, a life sciences focused special purpose acquisition company, until its merger with Jasper Therapeutics in September 2021.
  • Prior to that, Mr. Kapoor was Chief Business Officer of Iveric bio (formerly known as Ophthotech).
  • His track record of successful industry experience speaks for itself, and we look forward to benefiting from his strategic counsel.”